vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and GAIA, INC (GAIA). Click either name above to swap in a different company.
GAIA, INC is the larger business by last-quarter revenue ($25.5M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). GAIA, INC runs the higher net margin — -0.3% vs -0.8%, a 0.5% gap on every dollar of revenue. On growth, GAIA, INC posted the faster year-over-year revenue change (5.8% vs -25.7%). GAIA, INC produced more free cash flow last quarter ($76.0K vs $-15.8M). Over the past eight quarters, GAIA, INC's revenue compounded faster (9.4% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Gaia, Inc. is a publicly traded (NASDAQ:GAIA) American media company founded in 1988 by Jirka Rysavy in Louisville, Colorado. It owns and operates Gaia TV, a subscription video on-demand service consisting of original and licensed alternative media documentaries, including those on wellness, spirituality and conspiracy theories.
CTMX vs GAIA — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $25.5M |
| Net Profit | $-154.0K | $-75.0K |
| Gross Margin | — | 87.6% |
| Operating Margin | -6.9% | -2.6% |
| Net Margin | -0.8% | -0.3% |
| Revenue YoY | -25.7% | 5.8% |
| Net Profit YoY | 97.6% | 91.7% |
| EPS (diluted) | — | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $25.5M | ||
| Q3 25 | — | $25.0M | ||
| Q2 25 | $18.7M | $24.6M | ||
| Q1 25 | $50.9M | $23.8M | ||
| Q4 24 | $38.1M | $24.1M | ||
| Q3 24 | $33.4M | $22.0M | ||
| Q2 24 | $25.1M | $21.9M | ||
| Q1 24 | $41.5M | $21.3M |
| Q4 25 | — | $-75.0K | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $-154.0K | $-2.0M | ||
| Q1 25 | $23.5M | $-1.2M | ||
| Q4 24 | $18.9M | $-907.0K | ||
| Q3 24 | $5.7M | $-1.2M | ||
| Q2 24 | $-6.5M | $-2.2M | ||
| Q1 24 | $13.8M | $-971.0K |
| Q4 25 | — | 87.6% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 86.7% | ||
| Q1 25 | — | 87.7% | ||
| Q4 24 | — | 88.2% | ||
| Q3 24 | — | 86.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
| Q4 25 | — | -2.6% | ||
| Q3 25 | — | -5.0% | ||
| Q2 25 | -6.9% | -8.9% | ||
| Q1 25 | 44.4% | -4.3% | ||
| Q4 24 | 46.4% | -7.1% | ||
| Q3 24 | 12.3% | -5.3% | ||
| Q2 24 | -33.7% | -9.1% | ||
| Q1 24 | 28.1% | -4.0% |
| Q4 25 | — | -0.3% | ||
| Q3 25 | — | -4.6% | ||
| Q2 25 | -0.8% | -8.3% | ||
| Q1 25 | 46.2% | -5.1% | ||
| Q4 24 | 49.6% | -3.8% | ||
| Q3 24 | 17.2% | -5.4% | ||
| Q2 24 | -26.0% | -9.9% | ||
| Q1 24 | 33.3% | -4.6% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | — | $-0.05 | ||
| Q2 25 | — | $-0.07 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.03 | ||
| Q3 24 | — | $-0.05 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $13.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $87.9M |
| Total Assets | $175.1M | $154.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $13.5M | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | $49.0M | $13.9M | ||
| Q1 25 | $47.6M | $13.1M | ||
| Q4 24 | $38.1M | $5.9M | ||
| Q3 24 | $40.6M | $4.4M | ||
| Q2 24 | $43.2M | $5.5M | ||
| Q1 24 | $36.2M | $8.6M |
| Q4 25 | — | $87.9M | ||
| Q3 25 | — | $86.3M | ||
| Q2 25 | $119.9M | $85.7M | ||
| Q1 25 | $25.0M | $87.0M | ||
| Q4 24 | $-456.0K | $80.7M | ||
| Q3 24 | $-23.5M | $81.2M | ||
| Q2 24 | $-31.2M | $82.1M | ||
| Q1 24 | $-31.7M | $84.8M |
| Q4 25 | — | $154.6M | ||
| Q3 25 | — | $151.1M | ||
| Q2 25 | $175.1M | $147.0M | ||
| Q1 25 | $98.5M | $148.5M | ||
| Q4 24 | $120.5M | $141.2M | ||
| Q3 24 | $139.0M | $139.6M | ||
| Q2 24 | $159.2M | $142.1M | ||
| Q1 24 | $184.7M | $133.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $1.8M |
| Free Cash FlowOCF − Capex | $-15.8M | $76.0K |
| FCF MarginFCF / Revenue | -84.6% | 0.3% |
| Capex IntensityCapex / Revenue | 0.1% | 6.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-377.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $326.0K | ||
| Q2 25 | $-15.8M | $2.3M | ||
| Q1 25 | $-21.0M | $1.3M | ||
| Q4 24 | $-19.9M | $2.7M | ||
| Q3 24 | $-20.7M | $409.0K | ||
| Q2 24 | $-19.5M | $-2.1M | ||
| Q1 24 | $-26.0M | $5.9M |
| Q4 25 | — | $76.0K | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | $-15.8M | $880.0K | ||
| Q1 25 | $-21.2M | $268.0K | ||
| Q4 24 | $-20.0M | $1.6M | ||
| Q3 24 | $-20.7M | $-952.0K | ||
| Q2 24 | $-19.6M | $-3.5M | ||
| Q1 24 | $-26.2M | $4.9M |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | -6.4% | ||
| Q2 25 | -84.6% | 3.6% | ||
| Q1 25 | -41.6% | 1.1% | ||
| Q4 24 | -52.5% | 6.5% | ||
| Q3 24 | -62.1% | -4.3% | ||
| Q2 24 | -78.2% | -16.1% | ||
| Q1 24 | -63.1% | 22.8% |
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 7.7% | ||
| Q2 25 | 0.1% | 5.7% | ||
| Q1 25 | 0.2% | 4.3% | ||
| Q4 24 | 0.2% | 4.6% | ||
| Q3 24 | 0.1% | 6.2% | ||
| Q2 24 | 0.4% | 6.6% | ||
| Q1 24 | 0.3% | 5.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
GAIA
| US | $16.7M | 65% |
| Non Us | $8.8M | 35% |
